About Anelixis Therapeutics
Anelixis Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2013, and was acquired by Eledon in September 2020. CD40 and SOD1 targeting drugs are developed for ALS treatment. Anelixis Therapeutics has raised $12.86 million across 5 funding rounds from investors including Eledon and BVF Partners. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Neuromuscular. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Anelixis Therapeutics, a subsidiary of ALS Therapy Development Institute (ALS TDI), is focussed on developing drugs for Amyotrophic lateral sclerosis (ALS). It currently has 2 clinical programs targeting the CD40, Tumor Necrosis Factor (TNF) and superoxide dismutase (SOD1) which play a role in the pathogenesis of ALS. In addition to the clinical assets, it has issued patents for the method of treatment of neurodegenerative diseases by targeting CD40 and the targeting of CD8 T-Lymphocytes to treat neurodegenerative diseases.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website anelixistherapeutics.com
- Acquired by Eledon (Sep 2020)
Funding Insights of Anelixis Therapeutics
Anelixis Therapeutics has successfully raised a total of $12.86M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $6 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.86M
- Total Rounds 5
- Last Round Series B — $6M
- First Round $4.29M
(Jun 2017)
- Investors Count 1
All 5 funding rounds of Anelixis Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $6M | Series B | – | – | – |
| Nov 2019 | Series B | – | BVF Partners | – | |
| May 2019 | $1M | Debt – Conventional | – | – | – |
| Apr 2018 | $2.57M | Series A | – | – | – |
| Jun 2017 | $4.29M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Anelixis Therapeutics
Anelixis Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Eledon and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed. | 2004 | eledon.com | Irvine, United States |
Investor details for Anelixis Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Anelixis Therapeutics
4 dated milestones of Anelixis Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Anelixis Therapeutics is founded.
- Funding First funding round of $4.3M.
- Funding Latest funding round, Series B, of $6.0M.
- Exit Acquired by Eledon.
Competitors of Anelixis Therapeutics
Anelixis Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Anelixis Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Anelixis Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anelixis Therapeutics
Complete news archive for Anelixis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anelixis Therapeutics
Anelixis Therapeutics was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Anelixis Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Anelixis Therapeutics is a funded company, having raised a total of $12.86M across 5 funding rounds to date. The company's 1st funding round was a Series A of $4.29M, raised on Jun 2017.
Anelixis Therapeutics, a subsidiary of ALS Therapy Development Institute (ALS TDI), is focussed on developing drugs for Amyotrophic lateral sclerosis (ALS). It currently has 2 clinical programs targeting the CD40, Tumor Necrosis Factor (TNF) and superoxide dismutase (SOD1) which play a role in the pathogenesis of ALS. In addition to the clinical assets, it has issued patents for the method of treatment of neurodegenerative diseases by targeting CD40 and the targeting of CD8 T-Lymphocytes to treat neurodegenerative diseases.
Anelixis Therapeutics's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Anelixis Therapeutics has 2 investors. Key investors include Eledon, and BVF Partners.
Yes. Anelixis Therapeutics was acquired by Eledon in September 2020.